Share on StockTwits

OHR Pharmaceutical (NASDAQ:OHRP) Director June Sherie Almenoff acquired 2,200 shares of the company’s stock in a transaction that occurred on Wednesday, September 3rd. The shares were purchased at an average price of $8.08 per share, for a total transaction of $17,776.00. Following the completion of the purchase, the director now directly owns 127,566 shares in the company, valued at approximately $1,030,733. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

OHR Pharmaceutical (NASDAQ:OHRP) traded down 1.77% on Thursday, hitting $7.77. 116,638 shares of the company’s stock traded hands. OHR Pharmaceutical has a one year low of $6.01 and a one year high of $20.00. The stock has a 50-day moving average of $8.5 and a 200-day moving average of $10.56. The company’s market cap is $193.2 million.

Separately, analysts at Brean Capital raised their price target on shares of OHR Pharmaceutical from $21.00 to $34.00 in a research note on Tuesday, June 24th. They now have a “buy” rating on the stock.

Ohr Pharmaceutical Inc (NASDAQ:OHRP) is a biotechnology rollup company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.